Last reviewed · How we verify
MIS
MIS is a blood product derived from donated human blood that restores or replaces deficient blood components.
MIS is a blood product derived from pooled human plasma that provides passive immunization through multiple immunoglobulins and clotting factors. Used for Immunoglobulin deficiency or replacement therapy, Hemostatic support in coagulation disorders.
At a glance
| Generic name | MIS |
|---|---|
| Sponsor | Blood Transfusion Centre of Slovenia |
| Drug class | Plasma-derived immunoglobulin preparation or blood product |
| Modality | Biologic |
| Therapeutic area | Hematology / Immunology |
| Phase | FDA-approved |
Mechanism of action
MIS (likely a blood transfusion product or blood-derived therapeutic) functions by providing essential blood components such as red blood cells, platelets, plasma proteins, or clotting factors to patients with deficiencies due to blood loss, disease, or medical procedures. The exact mechanism depends on the specific blood product formulation, but generally works through volume replacement, oxygen-carrying capacity restoration, or hemostatic support.
Approved indications
- Blood loss requiring transfusion support
- Anemia or hemoglobin deficiency
- Thrombocytopenia or platelet deficiency
- Coagulopathy or clotting factor deficiency
Common side effects
- Transfusion reaction (acute hemolytic)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Infection transmission risk
Key clinical trials
- Functional Ovarian Reserve in Sickle Cell Disease
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- Lumbar & Sacroiliac Fusion Study Involving Previously Implanted Devices (NA)
- PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics
- Clariance ErYs Registry
- Biologicals in Management of Intra-Bony Defects (NA)
- Watchful Waiting Versus Immediate Repair for Occult Contralateral Inguinal Hernias. (NA)
- Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIS CI brief — competitive landscape report
- MIS updates RSS · CI watch RSS
- Blood Transfusion Centre of Slovenia portfolio CI